🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to researchers.

An International Challenge

The sexually transmitted infection are increasing worldwide, with figures suggesting over 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Results and Worldwide Availability

As per results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study enrolled over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of developing nations.

Clinicians on the front lines have expressed hope. Access to a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is considered essential to lessen the impact of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.